Suspension of trading

Analyst Reco. CureVac

Equities

Delayed Nasdaq Other stock markets 04:00:00 2026-01-05 pm EST			5-day change	1st Jan Change
4.660 ^USD	-0.21%		-.--%	+3.10%

Apr. 15	Evotec Taps CureVac Executive as COO	MT
Jan. 06	CureVac ends coverage after BioNTech acquisition

Jan. 06	CureVac ends coverage after BioNTech acquisition
Nov. 25	CureVac acquisition advances as cash runway secured to 2028
25-08-18	CureVac: Despite weak Q2, acquisition remains on track
25-07-14	CureVac: Pipeline pruning’s nasty effect
25-06-26	UBS Downgrades CureVac to Neutral From Buy, Adjusts Price Target to $5.50 From $12	MT
25-06-13	Jefferies Downgrades CureVac to Hold From Buy, $5 Price Target	MT
25-06-13	CUREVAC : Downgraded to Neutral by Jefferies	ZD
25-06-01	CureVac: Successful cash burn reduction
25-04-30	UBS Trims Price Target on CureVac to $12 From $13, Maintains Buy Rating	MT
25-04-11	CureVac: 2025 will be less costly
25-02-21	CureVac: The mid-term effect of pipeline pruning
24-12-12	CureVac: Licensing deal boosts bank account
24-12-08	CureVac: Positive one-off overshadows pipeline dryness
24-09-02	CUREVAC : Deutsche Bank reiterates its Neutral rating	ZD
24-08-31	CureVac: A beneficial deal
24-08-20	CureVac: Much noise at CureVac, overshadowing recent positive pipeline progress
24-05-23	CureVac: Significant cash drain in the Q1
24-05-02	CureVac: A missed opportunity
24-04-26	UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating	MT
24-04-25	Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4	MT
23-12-22	Kempen Upgrades CureVac to Buy From Neutral, Price Target is $10	MT
23-11-29	CUREVAC : An untrimmed pipeline becomes costly
23-11-28	CUREVAC : Unchanged cash drain
23-08-21	CUREVAC : A missed opportunity
23-07-25	CUREVAC : Higher losses expected in future